Primary composite endpoint at 12 months of serum alkaline phosphatase and bilirubin was met by 61.7% of patients treated with seladelpar 10 mg vs. 20.0% of placebo treated patients (p<0.0001) ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress Dr. Agarwal presented the following data from 38 of 40 patients that were on stable NA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback